These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 38363830)
1. STING licensing of type I dendritic cells potentiates antitumor immunity. Wang J; Li S; Wang M; Wang X; Chen S; Sun Z; Ren X; Huang G; Sumer BD; Yan N; Fu YX; Gao J Sci Immunol; 2024 Feb; 9(92):eadj3945. PubMed ID: 38363830 [TBL] [Abstract][Full Text] [Related]
2. STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity. Wang J; Li S; Wang M; Wang X; Chen S; Sun Z; Ren X; Huang G; Sumer BD; Yan N; Fu YX; Gao J bioRxiv; 2024 Jan; ():. PubMed ID: 38260493 [TBL] [Abstract][Full Text] [Related]
3. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. de Mingo Pulido Á; Hänggi K; Celias DP; Gardner A; Li J; Batista-Bittencourt B; Mohamed E; Trillo-Tinoco J; Osunmakinde O; Peña R; Onimus A; Kaisho T; Kaufmann J; McEachern K; Soliman H; Luca VC; Rodriguez PC; Yu X; Ruffell B Immunity; 2021 Jun; 54(6):1154-1167.e7. PubMed ID: 33979578 [TBL] [Abstract][Full Text] [Related]
4. Batf3-dependent orchestration of the robust Th1 responses and fungal control during cryptococcal infection, the role of cDC1. Xu J; Hissong R; Bareis R; Creech A; Goughenour KD; Freeman CM; Olszewski MA mBio; 2024 Mar; 15(3):e0285323. PubMed ID: 38349130 [TBL] [Abstract][Full Text] [Related]
5. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235 [TBL] [Abstract][Full Text] [Related]
6. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer. Yan X; Yao C; Fang C; Han M; Gong C; Hu D; Shen W; Wang L; Li S; Zhu S Int J Biol Sci; 2022; 18(2):585-598. PubMed ID: 35002511 [No Abstract] [Full Text] [Related]
8. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589 [TBL] [Abstract][Full Text] [Related]
9. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer. Ni H; Zhang H; Li L; Huang H; Guo H; Zhang L; Li C; Xu JX; Nie CP; Li K; Zhang X; Xia X; Li J J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36126994 [TBL] [Abstract][Full Text] [Related]
10. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445 [TBL] [Abstract][Full Text] [Related]
11. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections. Yum S; Li M; Fang Y; Chen ZJ Proc Natl Acad Sci U S A; 2021 Apr; 118(14):. PubMed ID: 33785602 [TBL] [Abstract][Full Text] [Related]
12. STING Signaling in Cancer Cells: Important or Not? Sokolowska O; Nowis D Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):125-132. PubMed ID: 28748479 [TBL] [Abstract][Full Text] [Related]
13. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553 [TBL] [Abstract][Full Text] [Related]
14. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy. Teijeira A; Garasa S; Luri-Rey C; de Andrea C; Gato M; Molina C; Kaisho T; Cirella A; Azpilikueta A; Wculek SK; Egea J; Olivera I; Rodriguez I; Rouzaut A; Verkhusha V; Valencia K; Sancho D; Berraondo P; Melero I Cancer Res; 2022 Dec; 82(23):4373-4385. PubMed ID: 36130020 [TBL] [Abstract][Full Text] [Related]
15. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases. Zhou S; Cheng F; Zhang Y; Su T; Zhu G Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125 [TBL] [Abstract][Full Text] [Related]
16. cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors. Li G; Zhao X; Zheng Z; Zhang H; Wu Y; Shen Y; Chen Q Cell Mol Life Sci; 2024 Mar; 81(1):149. PubMed ID: 38512518 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993 [TBL] [Abstract][Full Text] [Related]